204 related articles for article (PubMed ID: 20015894)
1. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.
Steinemann D; Arning L; Praulich I; Stuhrmann M; Hasle H; Stary J; Schlegelberger B; Niemeyer CM; Flotho C
Haematologica; 2010 Feb; 95(2):320-3. PubMed ID: 20015894
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
[TBL] [Abstract][Full Text] [Related]
3. Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
Ramamoorthy S; Lebrecht D; Schanze D; Schanze I; Wieland I; Andrieux G; Metzger P; Hess M; Albert MH; Borkhardt A; Bresters D; Buechner J; Catala A; De Haas V; Dworzak M; Erlacher M; Hasle H; Jahnukainen K; Locatelli F; Masetti R; Stary J; Turkiewicz D; Vinci L; Wlodarski MW; Yoshimi A; Boerries M; Niemeyer CM; Zenker M; Flotho C
Br J Haematol; 2024 Feb; 204(2):595-605. PubMed ID: 37945316
[TBL] [Abstract][Full Text] [Related]
4. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.
Side LE; Emanuel PD; Taylor B; Franklin J; Thompson P; Castleberry RP; Shannon KM
Blood; 1998 Jul; 92(1):267-72. PubMed ID: 9639526
[TBL] [Abstract][Full Text] [Related]
6. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies.
Stephens K; Weaver M; Leppig KA; Maruyama K; Emanuel PD; Le Beau MM; Shannon KM
Blood; 2006 Sep; 108(5):1684-9. PubMed ID: 16690971
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromatosis type 1 diagnosed in a child based on multiple juvenile xanthogranulomas and juvenile myelomonocytic leukemia.
Jans SR; Schomerus E; Bygum A
Pediatr Dermatol; 2015; 32(1):e29-32. PubMed ID: 25516272
[TBL] [Abstract][Full Text] [Related]
8. Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Wiesner SM; Geurts JL; Diers MD; Bergerson RJ; Hasz DE; Morgan KJ; Largaespada DA
Am J Hematol; 2011 Jul; 86(7):579-85. PubMed ID: 21681782
[TBL] [Abstract][Full Text] [Related]
9. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
10. Implications of mosaicism in variant interpretation: A case of a de novo homozygous NF1 variant.
Alghamdi M; Monies D; Alsohime F; Temsah H; Almodaihsh F; Aldawasri M; Alsultan A; Alkuraya FS
Eur J Med Genet; 2021 Jul; 64(7):104236. PubMed ID: 33965620
[TBL] [Abstract][Full Text] [Related]
11. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Chang T; Krisman K; Theobald EH; Xu J; Akutagawa J; Lauchle JO; Kogan S; Braun BS; Shannon K
J Clin Invest; 2013 Jan; 123(1):335-9. PubMed ID: 23221337
[TBL] [Abstract][Full Text] [Related]
12. Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia.
Raygada M; Arthur DC; Wayne AS; Rennert OM; Toretsky JA; Stratakis CA
Pediatr Blood Cancer; 2010 Jan; 54(1):173-5. PubMed ID: 19785027
[TBL] [Abstract][Full Text] [Related]
13. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
[TBL] [Abstract][Full Text] [Related]
14. Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-associated glomus tumors.
Stewart DR; Pemov A; Van Loo P; Beert E; Brems H; Sciot R; Claes K; Pak E; Dutra A; Lee CC; Legius E
Genes Chromosomes Cancer; 2012 May; 51(5):429-37. PubMed ID: 22250039
[TBL] [Abstract][Full Text] [Related]
15. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
[TBL] [Abstract][Full Text] [Related]
16. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
17. NF1 Somatic Mutation in Dystrophic Scoliosis.
Margraf RL; VanSant-Webb C; Mao R; Viskochil DH; Carey J; Hanson H; D'Astous J; Grossmann A; Stevenson DA
J Mol Neurosci; 2019 May; 68(1):11-18. PubMed ID: 30778836
[TBL] [Abstract][Full Text] [Related]
18. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
19. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.
Miles DK; Freedman MH; Stephens K; Pallavicini M; Sievers EL; Weaver M; Grunberger T; Thompson P; Shannon KM
Blood; 1996 Dec; 88(11):4314-20. PubMed ID: 8943868
[TBL] [Abstract][Full Text] [Related]
20. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
Sachs Z; Been RA; DeCoursin KJ; Nguyen HT; Mohd Hassan NA; Noble-Orcutt KE; Eckfeldt CE; Pomeroy EJ; Diaz-Flores E; Geurts JL; Diers MD; Hasz DE; Morgan KJ; MacMillan ML; Shannon KM; Largaespada DA; Wiesner SM
Haematologica; 2016 Oct; 101(10):1190-1199. PubMed ID: 27418650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
